acamprosate calcium NDC 70518-4616

NDC codes

FDA NDC Directory

Product NDC (as listed)70518-4616Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70518-4616Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70518-4616-0	70518461600	50 POUCH in 1 BOX (70518-4616-0) / 1 TABLET, DELAYED RELEASE in 1 POUCH (70518-4616-1)Marketed from Apr 23, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): acamprosate calcium
Generic name (nonproprietary): acamprosate calcium
Active ingredients: Acamprosate calcium — 333 mg/1
Dosage form: Tablet, Delayed release
Route: Oral
Labeler: REMEDYREPACK INC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205995
Marketing start: Apr 23, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 70518-4616_5216f438-5ac5-eb94-e063-6394a90a5d5cSPL ID 5216f438-5ac5-eb94-e063-6394a90a5d5cSPL set ID 91769a96-3182-4e38-90c3-b22c1beae398RxCUI 835726UNII 59375N1D0U

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470518461600 followed by a unit qualifier and the quantity

Package 70518-4616-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 18, 2026.

Indications (excerpt from the label)

Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation ( 1 , 14 ). Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support ( 1 ). Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. The efficacy of aca…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 205995

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 205995
Product	Strength	Form · route	Labeler	Product NDC
acamprosate calcium	Acamprosate calcium 333 mg/1	Tablet, Delayed releaseOral	Zydus Lifesciences Limited	70771-1057
acamprosate calcium	Acamprosate calcium 333 mg/1	Tablet, Delayed releaseOral	Zydus Pharmaceuticals (USA) Inc.	68382-569